Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First experience of a hemophilia monitoring platform: florio HAEMO.
Zapotocka E, Batorova A, Bilic E, Boban A, Escuriola Ettingshausen C, Faganel Kotnik B, Hrdlickova R, Laguna P, Machal J, Nemes L, Zupan IP, Puras G, Zombori M. Zapotocka E, et al. Among authors: escuriola ettingshausen c. Res Pract Thromb Haemost. 2022 Mar 13;6(2):e12685. doi: 10.1002/rth2.12685. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35308098 Free PMC article.
Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
Escuriola Ettingshausen C, Hegemann I, Simpson ML, Cuker A, Kulkarni R, Pruthi RK, Garly ML, Meldgaard RM, Persson P, Klamroth R. Escuriola Ettingshausen C, et al. Res Pract Thromb Haemost. 2019 Mar 23;3(2):268-276. doi: 10.1002/rth2.12192. eCollection 2019 Apr. Res Pract Thromb Haemost. 2019. PMID: 31011711 Free PMC article.
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group. Carcao M, et al. Among authors: escuriola ettingshausen c. Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29. Haemophilia. 2019. PMID: 31033112 Free PMC article.
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.
Escuriola Ettingshausen C, Vdovin V, Zozulya N, Svirin P, Andreeva T, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Zupancic-Šalek S, Pavlova A, Bátorová A, Montaño Mejía C, Abdilova G, Knaub S, Jansen M, Lowndes S, Belyanskaya L, Walter O, Oldenburg J; ObsITI Study Group. Escuriola Ettingshausen C, et al. TH Open. 2022 May 26;6(2):e124-e134. doi: 10.1055/s-0042-1748756. eCollection 2022 Apr. TH Open. 2022. PMID: 35707623 Free PMC article.
Inhibitor development and mortality in non-severe hemophilia A.
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Eckhardt CL, et al. J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10. J Thromb Haemost. 2015. PMID: 25912309 Free article.
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K. van Velzen AS, et al. Among authors: escuriola ettingshausen c. J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2. J Thromb Haemost. 2017. PMID: 28440011 Free article.
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group. Mancuso ME, et al. Among authors: escuriola ettingshausen c. Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6. Thromb Haemost. 2017. PMID: 29212115
Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S, Crampe C, Dargaud Y, Lavigne-Lissalde G, Escuriola-Ettingshausen C, Tardy B, Meley R, Thouvenin S, Stephan JL, Berger C. Mathieu S, et al. Among authors: escuriola ettingshausen c. Blood Coagul Fibrinolysis. 2015 Dec;26(8):940-5. doi: 10.1097/MBC.0000000000000300. Blood Coagul Fibrinolysis. 2015. PMID: 26517064
48 results